文献速递支持与姑息治疗

关于医用大麻用于癌症诊疗的知识、态度与临床使用模式的国际调查:TASMAN研究

An international survey on the knowledge, attitudes and clinical patterns of use of medical cannabis for cancer care: The TASMAN study.
PubMed 文献 · Eur J Cancer · 2024-11-30

TASMAN研究通过问卷调查全球肿瘤科与姑息治疗提供者对医用大麻(MC)的知识、态度与实践,共纳入179名参与者(应答率51.1%)。结果显示92.7%的受访者不了解MC临床指南,84.4%不常规处方MC,MC使用与患者请求在高收入国家和EURO地区更常见。作者结论认为需要更清晰的法规、标准化指南和针对性教育。

要点

  • 92.7%的受访者不了解医用大麻的临床指南。
  • 84.4%的受访者不常规处方医用大麻。
  • 医用大麻使用与患者请求在高收入国家和EURO地区更常见。

核心结论

  • 作者结论认为,更清晰的法规、标准化指南和针对性教育对于支持医用大麻安全整合入肿瘤与姑息治疗至关重要。
  • 作者认为上述措施最终可改善癌症患者的生活质量。

研究设计与样本

  • TASMAN研究旨在评估全球肿瘤科与姑息治疗提供者对医用大麻用于癌症诊疗的知识、态度与实践。
  • 研究对来自不同地区和收入水平的医疗提供者进行了问卷调查,共纳入179名参与者,应答率51.1%。

主要发现

  • 参与者中女性占49.4%,中位年龄37岁,肿瘤科医生占71.5%,在大学医院执业者占40.2%,在癌症中心执业者占32.4%,超过半数来自低收入和中等收入国家。
  • 92.7%的受访者不了解医用大麻的临床指南,44.1%熟悉医用大麻的使用,78.8%认识到其在癌痛中的作用,34%认识到其在管理恶病质中的作用。
  • 仅10%的受访者熟悉特定大麻产品,84.4%的受访者不常规处方医用大麻。
  • 大多数参与者对法律地位和法规不明确,40%指出大麻为非法。
  • 医用大麻使用与患者请求在高收入国家和EURO地区更常见,姑息治疗提供者的认知和处方率最高。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Medical cannabis (MC) has gained traction in oncology for managing cancer-related symptoms, but its integration faces challenges due to limited evidence, inconsistent guidelines, and varied legal frameworks. METHODS: The TASMAN study aimed to assess the knowledge, attitudes, and practices of oncologists and palliative care providers globally regarding MC use in cancer care. A survey of healthcare providers from diverse regions and income levels was conducted. RESULTS: we study included 179 participants (response rate: 51.1 %), with an equal gender distribution (49.4 % female) and a median age of 37 years. Participants were primarily oncologists (71.5 %), practicing in university hospitals (40.2 %) or cancer centres (32.4 %), with over half from low- and middle-income countries. Most respondents (92.7 %) were unaware of clinical guidelines for MC. A proportion of 44.1 % were familiar with MC use, 78.8 % recognized its role in cancer pain, and 34 % identified its role in managing cachexia. Awareness of specific products was low, with only 10 % familiar with specific cannabis products. Three-quarters of respondents (84.4 %) did not prescribe MC routinely. Legal status and regulations were unclear for most participants; 40 % noted cannabis as illegal. MC use and patient requests were more common in high-income countries and the EURO region, with palliative care providers demonstrating the highest awareness and prescription rates. CONCLUSION: Clearer regulations, standardized guidelines, and targeted education are essential to support the safe integration of MC into oncology and palliative care, ultimately improving the quality of life for cancer patients.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Trapani D, Nidhamalddin SJ, Gandini S, et al. An international survey on the knowledge, attitudes and clinical patterns of use of medical cannabis for cancer care: The TASMAN study. Eur J Cancer. 2024. PMID: 39647216. doi:10.1016/j.ejca.2024.115158

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。